and AstraZeneca: Speaking and Teaching, Tsunamasa Watanabe: Nothing to Disclose, Masaru Enomoto: Nothing to Disclose, Carmen Preda: Nothing to Disclose, Masanori Atsukawa: Nothing to Disclose, Sebastin Marciano: Nothing to Disclose, Son Do: Nothing to Disclose, Daniel Huang: Nothing to Disclose, Christopher Wong: Nothing to Disclose, Haruki Uojima: Nothing to Disclose, Hirokazu Takahashi: Nothing to Disclose, Htet Htet Toe Wai Khine: Nothing to Disclose, Takashi Honda: Nothing to Disclose, Norio Itokawa: Nothing to Disclose, Min Seok Go: Nothing to Disclose 403 FACTORS AND PREDICTION MODEL OF HBSAG RELAPSE AFTER ACHIEVING CLINICAL CURE IN CHB PATIENTS WITH PEG IFN-2B Jing Chen 1 fei yan 1 Jiayin Wang 2 Jing Liang 2 Jun Li 2 Fang Wang 2 Qing Ye 2 Yanying Gao 2 Weili Yin 2 Fei Tang 2 Huiling Xiang 2 , 1 The Third Central Clinical College of Tianjin Medical University, 2 Tianjin Third Central Hospital Background: Due to the existence of cccDNA in hepatocytes, there is still a portion of patients with HBsAg relapse after HBsAg seroclearance with interferon, and the predictive factors of whether HBsAg is recurrent are still in the exploratory stage
received funding from Paris Sciences et Lettres University/lUniversit Cte dAzur (PSL/OCAV)
FIGURE 2 Inhibition of Sat1 alleviates MIRI by regulating ferroptosis in vivo To further investigate the role of Sat1 in MIRI in vivo , AAV9 was applied in SD rats to suppress Sat1 expression
Immune layer: Thymosin alpha-1 for those with documented Th2-dominant immune profiles seeking to restore balance
Prestwick_120 67
